CLINICAL COMPLIANCE 2011 - FDA Clinical Trial Auditing and the due diligence Companies should conduct as part of their monitoring program

Website http://complianceonline.com/ecommerce/control/trainingFocus/~product_id=701895?channel=ourglocalp:// | Edit Freely

Category Clinical Webinar ,conference,event.

Deadline: February 24, 2011 | Date: February 24, 2011

Venue/Country: Palo Alto, U.S.A

Updated: 2011-02-02 16:29:11 (GMT+9)

Call For Papers - CFP

The main principle is following exactly the signed and approved (IRB + PI) Protocol to the letter. This, in fact, is included on the FDA Form 1572.

In the current regulatory climate, GCP Investigator site audits are a part of the clinical trial process. Sponsors should anticipate more inspections and information requests regarding monitoring practices. Many monitoring systems lack components that ensure proper management of the research site.

Monitoring systems should include specific components to ensure control of investigational product, data integrity, oversight of investigators as well as other areas. The components of a quality monitoring system will be presented so that participants can assess their current practices for identifying gaps and risks, particularly in relation to preparing for regulatory inspections.

It will be important to see what the FDA regulations and the ICH GCP recommendations are in this regard. The key is that the PI and all clinical staff know and follow the research plan (Protocol) exactly as it is written. To do this is ethical research. To not follow the protocol and document study conduct carelessly is folly.

NOTE: Use This Promocode ( 117660 ) To Get 10% Discount.